Navigation Links
FDA Adds More Warnings to Antidepressant's Label
Date:3/28/2012

WEDNESDAY, March 28 (HealthDay News) -- In a follow-up to a warning that high doses of the popular antidepressant Celexa can cause potentially fatal abnormal heart rhythms, the U.S. Food and Drug Administration has issued new dosing and use recommendations.

Last August, the FDA said doses of Celexa (citalopram hydrobromide) greater than 40 milligrams a day can cause changes in the electrical activity of the heart, which can lead to abnormal heart rhythms, including a potentially deadly arrhythmia known as Torsade de Pointes.

Patients at high risk include those with preexisting heart conditions (including congestive heart failure) and those prone to low levels of potassium and magnesium in the blood, the FDA said.

At the time, the drug label was revised to include the new dosage limit as well as information about the potential for abnormal heart electrical activity and rhythms.

The latest recommendations note that Celexa in any dose should not be given to patients with certain conditions due to the risk of suffering these heart problems. However, it may be important for some patients to take Celexa, so the label has been changed to describe the particular cautions required when giving the drug to these patients.

Here are the latest FDA recommendations:

  • Celexa should not be used at doses greater than 40 milligrams (mg).
  • Celexa is not recommended for use in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent heart attack, or uncompensated heart failure.
  • Use of the Celexa is also not recommended in patients who are taking other drugs that prolong the QT interval, a measure of a heart's electrical activity.
  • The maximum recommended dose of Celexa is 20 mg per day for patients with liver impairment, patients who are older than 60, patients who are CYP 2C19 poor metabolizers, or patients who are also taking cimetidine (Tagamet) or another CYP 2C19 inhibitor. All of these factors lead to increased blood levels of Celexa, increasing the risk of QT interval prolongation and Torsade de Pointes, the FDA said.

Dr. Norman Sussman, a psychiatrist at NYU Langone Medical Center and a professor at NYU School of Medicine in New York City, said: "What the FDA's recommendations ultimately mean is that before prescribing, after prescribing and especially when considering starting a new drug, a physician in any specialty who is treating a patient taking citalopram should be certain of the effect the medication may have on the QT interval.

"These recommendations are basically a game changer for the way in which citalopram should be prescribed, and how patients taking citalopram should be monitored," he said.

Celexa belongs to a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs), which also include widely used medications such as Paxil, Prozac and Zoloft.

More information

The American Academy of Family Physicians has more about antidepressants.

-- Robert Preidt

SOURCEs: Norman Sussman, psychiatrist, NYU Langone Medical Center, and professor, NYU School of Medicine, New York City; U.S. Food and Drug Administration, news release, March 28, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. U.S. Will Push to Have Graphic Warnings on Cigarettes
2. Judge Blocks Plan for Graphic Cigarette Warnings
3. Judge Blocks FDA Plan for Graphic Cigarette Warnings
4. FDA Proposes Graphic Warnings on Cigarette Packs
5. FDA Calls for New Warnings on Some Prostate Cancer Drugs
6. Does the brain remember antidepressants?
7. Moms Antidepressants May Affect Babies Head Size: Study
8. Antidepressants While Pregnant Linked to Slight Risk of Lung Problem in Babies
9. Blood test might predict how well a depressed patient responds to antidepressants
10. Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients
11. Fear of Antidepressants Keep Many From Disclosing Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
Breaking Medicine Technology: